INNOVIVA, INC. Debt Conversion, Original Debt, Amount
INNOVIVA, INC. (INVA) reported Debt Conversion, Original Debt, Amount of $0 for the 12-month period ending 2016-12-31, per its 10-K filed 2017-02-28.
Discontinued › Cash Flow › Financing Activities
us-gaap:DebtConversionOriginalDebtAmount1 · last filed 2017-02-28
- INNOVIVA, INC. debt conversion, original debt, amount for the quarter ending 2015-12-31 was $0.00, a 100.00% decline year-over-year.
- INNOVIVA, INC. debt conversion, original debt, amount for the quarter ending 2014-12-31 was $64.78M.
- INNOVIVA, INC. debt conversion, original debt, amount for the quarter ending 2013-12-31 was $0.00.
- INNOVIVA, INC. debt conversion, original debt, amount for fiscal 2016 was $0.00.
- INNOVIVA, INC. debt conversion, original debt, amount for fiscal 2015 was $0.00, a 100.00% decline from fiscal 2014.
- INNOVIVA, INC. debt conversion, original debt, amount for fiscal 2014 was $32.39M.
- INNOVIVA, INC. debt conversion, original debt, amount for fiscal 2013 was -$172.50M.
| Period end | Debt Conversion, Original Debt, Amount 3 month | Debt Conversion, Original Debt, Amount 9 month | Debt Conversion, Original Debt, Amount 12 month | Debt Conversion, Original Debt, Amount 12 month as first filed |
|---|---|---|---|---|
| 2016-12-31 | $0.00 10-K · filed 2017-02-28 | |||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | $0.00 10-K · filed 2017-02-28 | ||
| 2015-09-30 | $0.00 10-Q · filed 2015-11-05 | |||
| 2014-12-31 | $64.78M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | $32.39M 10-K · filed 2017-02-28 | -$32.39M 10-K · filed 2015-02-27 | |
| 2014-09-30 | -$32.39M 10-Q · filed 2015-11-05 | |||
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-24 | -$172.50M 10-K · filed 2016-02-24 | ||
| 2013-09-30 | -$172.50M 10-Q · filed 2014-11-04 | |||
| 2012-12-31 | $0.00 10-K · filed 2015-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |